行情

ORMP

ORMP

Oramed
NASDAQ

实时行情|Nasdaq Last Sale

2.620
+0.110
+4.38%
休市 16:00 11/15 EST
开盘
2.500
昨收
2.510
最高
2.650
最低
2.418
成交量
8.80万
成交额
--
52周最高
4.500
52周最低
2.317
市值
4,554.44万
市盈率(TTM)
-3.0077
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ORMP 新闻

  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.2天前
  • Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th
  • PR Newswire.3天前
  • The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
  • Benzinga.4天前
  • AAP, SLDB among premarket losers
  • Seeking Alpha - Article.5天前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

ORMP 简况

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.
展开

Webull提供Oramed Pharmaceuticals, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。